Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Decreases By 27.1%

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 3,850,000 shares, a decline of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the days-to-cover ratio is presently 1.2 days.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently modified their holdings of the stock. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new position in Capricor Therapeutics during the third quarter valued at approximately $133,000. Bank of New York Mellon Corp increased its stake in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Capricor Therapeutics in the third quarter worth $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new stake in Capricor Therapeutics in the third quarter worth $192,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Finally, Maxim Group raised their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Down 0.2 %

Shares of Capricor Therapeutics stock traded down $0.03 during trading on Friday, reaching $19.01. 571,850 shares of the company were exchanged, compared to its average volume of 1,148,096. The business has a 50-day moving average price of $18.03 and a 200-day moving average price of $9.38. The firm has a market capitalization of $864.38 million, a price-to-earnings ratio of -17.93 and a beta of 4.00. Capricor Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.